Terms: = Lymphoma AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
148 results:
1. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular lymphoma.
Kahl BS; Jegede OA; Peterson C; Swinnen LJ; Habermann TM; Schuster SJ; Weiss M; Fishkin PA; Fenske TS; Williams ME
J Clin Oncol; 2024 Mar; 42(7):774-778. PubMed ID: 38194625
[No Abstract] [Full Text] [Related]
2. The association of environmental factors with neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia (ALL).
Nigro SE; Hall LP; Harman J; Willard VW; Conklin HM; Pui CH; Jeha S; Jacola LM
Support Care Cancer; 2023 Dec; 32(1):1. PubMed ID: 38047975
[TBL] [Abstract] [Full Text] [Related]
3. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
4. Serum Albumin Affects the Time-to-treatment Failure of Alectinib: A Multicenter Retrospective Study.
Umehara K; Yama K; Goto K; Hoshi T; Hatakeyama T; Isaji M; Takada S; Yamagishi K; Mino K; Sato H
In Vivo; 2023; 37(5):2260-2267. PubMed ID: 37652488
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of anti-apoptotic protein (Bcl-xl) levels and mRNA expression in infertile patients.
Hashem R; Al-Obaidi ZF; Samawi FT; Baher H
Afr J Reprod Health; 2022 Oct; 26(10):63-71. PubMed ID: 37585047
[TBL] [Abstract] [Full Text] [Related]
6. [Association of Geriatric Nutritional Risk Index with Adverse Events and Time to treatment Failure in Malignant lymphoma Patients Treated with(R-)EPOCH].
Kikuchi K; Yama K; Misaka H; Takeda G; Watanabe T; Souma T; Harada T; Lang L; Yamawaki F; Saga T; Ishihara T; Sato H
Gan To Kagaku Ryoho; 2023 Jun; 50(6):701-705. PubMed ID: 37317604
[TBL] [Abstract] [Full Text] [Related]
7. Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Correia C; Maurer MJ; McDonough SJ; Schneider PA; Ross PE; Novak AJ; Feldman AL; Cerhan JR; Slager SL; Witzig TE; Eckloff BW; Li H; Nowakowski GS; Kaufmann SH
Blood Cancer J; 2023 May; 13(1):81. PubMed ID: 37193683
[TBL] [Abstract] [Full Text] [Related]
8. Influence of Geriatric Nutritional Risk Index on Occurrence of Adverse Events and Duration of treatment in Patients With lymphoma Receiving R-CHOP Therapy.
Kikuchi K; Sawada M; Takeda G; Watanabe T; Souma T; Sato H
In Vivo; 2023; 37(3):1297-1303. PubMed ID: 37103079
[TBL] [Abstract] [Full Text] [Related]
9. Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method.
Bommier C; Lambert J; Nowakowski G; Zucca E; Thieblemont C
Hematol Oncol; 2022 Dec; 40(5):1086-1089. PubMed ID: 35299287
[TBL] [Abstract] [Full Text] [Related]
10. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Dourthe ME; Phulpin A; Auperin A; Bosq J; Couec ML; Dartigues P; Ducassou S; Garnier N; Haouy S; Leblanc T; Leruste A; Paillard C; Rigaud C; Simonin M; Patte C; Minard-Colin V
Haematologica; 2022 Sep; 107(9):2173-2182. PubMed ID: 35236054
[TBL] [Abstract] [Full Text] [Related]
11. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract] [Full Text] [Related]
12. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
[TBL] [Abstract] [Full Text] [Related]
14. Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study.
Jensen KS; Klug Albertsen B; Schrøder H; Zalounina Falborg A; Schmiegelow K; Rosthøj S; Callesen MT; Vedsted P
BMJ Open; 2021 Nov; 11(11):e049847. PubMed ID: 34810184
[TBL] [Abstract] [Full Text] [Related]
15. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N; Kirkwood AA; Lamb M; Smith A; Khwaja J; Manos K; Shrubsole C; Gray N; Lewis K; Tivey A; Bishton MJ; Hawkes E; Ahearne MJ; Osborne W; Collins GP; Illidge T; Linton KM; Cwynarski K; Burton C; Fox CP
Adv Ther; 2021 Jul; 38(7):3789-3802. PubMed ID: 34037958
[TBL] [Abstract] [Full Text] [Related]
16. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell lymphoma (DLBCL) in Switzerland.
Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
[TBL] [Abstract] [Full Text] [Related]
17. Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan.
Matsuda K; Jo T; Miyauchi M; Toyama K; Nakazaki K; Matsui H; Fushimi K; Yasunaga H; Kurokawa M
J Infect Chemother; 2021 Aug; 27(8):1151-1155. PubMed ID: 33745811
[TBL] [Abstract] [Full Text] [Related]
18. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
Ito K; Yamanaka T; Hayashi H; Hattori Y; Nishino K; Kobayashi H; Oya Y; Yokoyama T; Seto T; Azuma K; Fukui T; Kozuki T; Nakamura A; Tanaka K; Hirano K; Yokoi T; Daga H; Sakata S; Fujimoto D; Mori M; Maeno K; Aoki T; Tamura A; Miura S; Watanabe S; Akamatsu H; Hataji O; Suzuki K; Hontsu S; Azuma K; Bessho A; Kubo A; Okuno M; Nakagawa K; Yamamoto N
Eur J Cancer; 2021 Mar; 145():183-193. PubMed ID: 33486442
[TBL] [Abstract] [Full Text] [Related]
19. Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study.
Yan W; Wu B; Liao AJ; Yang W; Wang HH
Ann Hematol; 2021 Mar; 100(3):709-714. PubMed ID: 33483774
[TBL] [Abstract] [Full Text] [Related]
20. [Erythrophagocytosis by blast cells and de novo T cell LAL without cytogenetic abnormalities in a Moroccan patient].
Kahouli S; Zahid H; Khorassani ME; Kabbaj SE; Benkirane M; Messaoudi N
Pan Afr Med J; 2020; 36():202. PubMed ID: 32963668
[TBL] [Abstract] [Full Text] [Related]
[Next]
